Peritoneal dialysis (PD) solutions containing glucose are considered to cause peritoneal fibrosis. Plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) participate in fibrogenesis of various organs, and human peritoneal mesothelial cells (HPMC) can produce PAI-1 and t-PA following glucose stimulation. Icodextrin has been widely used as an alternative osmotic agent. In this study, we investigated whether icodextrin-based PD solution reduced the production of PAI-1 and t-PA by HPMC. We also examined the involvement of extracellular signal-regulated kinase 1/2 (ERK1/2). Glucose-based PD solutions increased the production of PAI-1 and t-PA by HPMC, whereas icodextrin-based PD solution exerted lesser effects. Glucose-based PD solutions activated ERK1/2, and PD98059 inhibited the production of PAI-1 and t-PA-responses not observed with icodextrin-based PD solution. In conclusion, glucose-based PD solutions, unlike icodextrin-based PD solution, induce overproduction of PAI-1 and t-PA via the ERK1/2 pathway.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1744-9987.2007.00423.xDOI Listing

Publication Analysis

Top Keywords

icodextrin-based solution
20
plasminogen activator
16
pai-1 t-pa
16
production pai-1
12
glucose-based solutions
12
activator inhibitor-1
8
tissue-type plasminogen
8
human peritoneal
8
peritoneal mesothelial
8
mesothelial cells
8

Similar Publications

Background: The stability of antimicrobials in peritonitis during peritoneal dialysis (PD) solutions is a critical factor influencing treatment success. This study investigated the stability of daptomycin (DAP) when combined with icodextrin-based PD solution, by measuring DAP concentrations and observing any structural changes.

Methods: A dose of DAP (350 mg) was dissolved in 7 mL of saline in a clean bench.

View Article and Find Full Text PDF

Can one long peritoneal dwell with icodextrin replace two short dwells with glucose?

Front Physiol

July 2024

Department of Clinical Science, Intervention and Technology, Division of Renal Medicine and Baxter Novum, Karolinska Institutet, Stockholm, Sweden.

Background: Due to the slower dissipation of the osmotic gradient, icodextrin-based solutions, compared to glucose-based solutions, can improve water removal. We investigated scenarios where one icodextrin-based long dwell (Extraneal) replaced two glucose-based exchanges.

Methods: The three-pore model with icodextrin hydrolysis was used for numerical simulations of a single exchange to investigate the impact of different peritoneal dialysis schedules on fluid and solute removal in patients with different peritoneal solute transfer rates (PSTRs).

View Article and Find Full Text PDF

Background: Oxidative stress (OxSt) and inflammation are common in CKD and are known CV and mortality risk factors. In peritoneal dialysis (PD) OxSt and Inflammation even increase due to the use of glucose-based solutions.

Patients And Methods: This study analyzed in 15 PD patients the effect of 3 and 6 months of treatment with icodextrin-based glucose-free solutions on OxSt and inflammation, evaluating p22 protein expression (Western blot), NADPH oxidase subunit, essential for OxSt activation, MYPT-1 phosphorylation state, marker of RhoA/Rho kinase pathway (ROCK) activity, involved in the induction of OxSt (Western blot) and Malondialdehyde (MDA) production (fluorimetric assay).

View Article and Find Full Text PDF

Icodextrin-induced acute generalized exanthematous pustulosis in a patient with peritoneal dialysis.

Nephrology (Carlton)

July 2024

Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Icodextrin has been widely prescribed for peritoneal dialysis (PD) patients with inadequate ultrafiltration, but icodextrin induced acute generalized exanthematous pustulosis (AGEP) has been not well recognized in clinical practice. We described a young-aged female with IgA nephropathy and end stage kidney disease under continuous automated peritoneal dialysis. She developed skin erythema with exfoliation over the groin 7th day after initiation of icodextrin based PD dialysate.

View Article and Find Full Text PDF
Article Synopsis
  • Volume overload is a serious issue for patients on peritoneal dialysis (PD), and traditional treatments often fall short, leading researchers to explore SGLT2 inhibitors as a potential new solution.
  • The EMPOWERED trial will investigate if the SGLT2 inhibitor empagliflozin can increase ultrafiltration volume in patients with chronic heart failure who use glucose-based PD solutions.
  • Results from this trial could provide valuable insights into fluid management and the impact of SGLT2 inhibitors on overall kidney function in PD patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!